BBI-4000 (sofpironium bromide)

Sofpironium bromide is a new molecular entity that recently underwent testing in a randomized, double-blind, vehicle-controlled Phase 2b clinical trial in patients with primary axillary (underarm) hyperhidrosis.. In this study, BBI-4000 (sofpironium bromide) gel was well-tolerated and achieved statistically significant and clinically meaningful results in patients with axillary hyperhidrosis. Based upon this encouraging data, we are moving BBI-4000 (sofprionium bromide) gel towards Phase 3 development.

Sofpironium bromide, a new molecular entity, belongs to a class of drugs called ‘anticholinergics,’ which exert their effect by blocking the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including the activation of sweat glands. Soft-anticholinergics, such as sofpironium bromide, exert their action topically and are rapidly metabolized into a considerably less active metabolite when they reach the blood system, thus potentially allowing for effective doses to be used while reducing the limiting systemic side effects associated with other drugs in this class. Sofpironium bromide was originally developed at Bodor Laboratories, Inc. by Dr. Nicholas Bodor, an internationally recognized leader in retrometabolic drug design approaches.